ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial

Cheng, Ying*; Han, Liang; Wu, Lin; Chen, Jun; Sun, Hongmei; Wen, Guilan; Ji, Yinghua; Dvorkin, Mikhail; Shi, Jianhua; Pan, Zhijie; Shi, Jinsheng; Wang, Xicheng; Bai, Yuansong; Melkadze, Tamar; Pan, Yueyin; Min, Xuhong; Viguro, Maksym; Li, Xingya; Zhao, Yanqiu; Yang, Junquan; Makharadze, Tamta; Arkania, Ekaterine; Kang, Wenying; Wang, Qingyu; Zhu, Jun广东药学院; 吉林大学; 南昌大学; 浙江大学; 郑州大学; 1; y
JAMA2022-9-27DOI: 10.1001/jama.2022.16464
88被引5阅读
引用收藏
分享

摘要

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC). It remained unknown whether adding a programmed cell death 1 (PD-1) inhibitor to chemotherapy provided similar or better benefits in patients with extensive-stage SCLC, which would add evidence on the efficacy of checkpoint inhibitors in the treatment of extensive-stage SCLC. Objective To evaluate the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC. Design, Setting, and Participants This international, double-blind, phase 3 randomized clinical trial (ASTRUM-005) enrolled patients at 114 hospital sites in 6 countries between September 12, 2019, and April 27, 2021. Of 894 patients who were screened, 585 with extensive-stage SCLC who had not previously received systemic therapy were randomized. Patients were followed up through October 22, 2021. Interventions Patients were randomized 2:1 to receive either 4.5 mg/kg of serplulimab (n = 389) or placebo (n = 196) intravenously every 3 weeks. All patients received intravenous carboplatin and etoposide every 3 weeks for up to 12 weeks. Main Outcomes and Measures The primary outcome was overall survival (prespecified significance threshold at the interim analysis, 2-sided P < .012). There were 13 secondary outcomes, including progression-free survival and adverse events. Results Among the 585 patients who were randomized (mean age, 61.1 [SD, 8.67] years; 104 [17.8%] women), 246 (42.1%) completed the trial and 465 (79.5%) discontinued study treatment. All patients received study treatment and were included in the primary analyses. As of the data cutoff (October 22, 2021) for this interim analysis, the median duration of follow-up was 12.3 months (range, 0.2-24.8 months). The median overall survival was significantly longer in the serplulimab group (15.4 months [95% CI, 13.3 months-not evaluable]) than in the placebo group (10.9 months [95% CI, 10.0-14.3 months]) (hazard ratio, 0.63 [95% CI, 0.49-0.82]; P < .001). The median progression-free survival (assessed by an independent radiology review committee) also was longer in the serplulimab group (5.7 months [95% CI, 5.5-6.9 months]) than in the placebo group (4.3 months [95% CI, 4.2-4.5 months]) (hazard ratio, 0.48 [95% CI, 0.38-0.59]). Treatment-related adverse events that were grade 3 or higher occurred in 129 patients (33.2%) in the serplulimab group and in 54 patients (27.6%) in the placebo group. Conclusions and Relevance Among patients with previously untreated extensive-stage SCLC, serplulimab plus chemotherapy significantly improved overall survival compared with chemotherapy alone, supporting the use of serplulimab plus chemotherapy as the first-line treatment for this patient population.

学科与关键词

关键词
CARBOPLATINCISPLATINETOPOSIDE
相关
加载中…
  • Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
    Li, Huijuan; Han, Hedong; Li, Chuling; Wu, Ranpu; Wang, Zhaofeng; Wang, Yimin; Zhan, Ping; Lv, Tangfeng; Zhang, Fang; Song, Yong*; Liu, Hongbing*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231189430.被引 1
  • Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Wang, Jie; Zhou, Caicun; Yao, Wenxiu; Wang, Qiming; Min, Xuhong; Chen, Gongyan; Xu, Xingxiang; Li, Xingya; Xu, Fei; Fang, Yong; Yang, Runxiang; Yu, Guohua; Gong, Youling; Zhao, Jun; Fan, Yun; Liu, Quan; Cao, Lejie; Yao, Yu; Liu, Yunpeng; Li, Xiaoling; Wu, Jingxun; He, Zhiyong; Lu, Kaihua; Jiang, Liyan; Hu, Chengping; Zhao, Wenhua; Zhang, Ben; Shi, Wei; Zhang, Xiaojing; Cheng, Ying*LANCET ONCOLOGY, 2022, 23(6): 739-747.被引 90
  • Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)
    Cheng, Y.; Han, L.; Wu, L.; Chen, J.; Sun, H.; Wen, G.; Ji, Y.; Dvorkin, M.; Shi, J.; Pan, Z.; Shi, J.; Wang, X.; Bai, Y.; Melkadze, T.; Pan, Y.; Min, X.; Viguro, M.; Kang, W.; Wang, Q.; Zhu, J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
查看全部 →

发表信息

论文状态
公开发表
期刊
JAMA
发表日期
2022-09-27
卷期
第 328 卷, 第 12 期
页码
1223-1232
DOI
10.1001/jama.2022.16464
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Shanghai Henlius Biotech, Inc.

作者

  • C

    Cheng, Ying (通讯) (第一作者)

  • H

    Han, Liang

查看全部 25 位作者收起作者
  • W

    Wu, Lin

    hunan canc hosp

  • C

    Chen, Jun

    tianjin med univ gen hosp

  • S

    Sun, Hongmei

  • W

    Wen, Guilan

    1 · nanchang univ

  • J

    Ji, Yinghua

    1 · xinxiang med univ

  • D

    Dvorkin, Mikhail

  • S

    Shi, Jianhua

  • P

    Pan, Zhijie

    1 · zhejiang univ

  • S

    Shi, Jinsheng

  • W

    Wang, Xicheng

    1 · guangdong pharmaceut univ

  • B

    Bai, Yuansong

    jilin univ

  • M

    Melkadze, Tamar

  • P

    Pan, Yueyin

    anhui prov hosp

  • M

    Min, Xuhong

  • V

    Viguro, Maksym

  • L

    Li, Xingya

    1 · zhengzhou univ

  • Z

    Zhao, Yanqiu

    zhengzhou univ

  • Y

    Yang, Junquan

  • M

    Makharadze, Tamta

  • A

    Arkania, Ekaterine

  • K

    Kang, Wenying

  • W

    Wang, Qingyu

  • Z

    Zhu, Jun

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417